title: The effect of EPA and DHA on metabolic syndrome patients: a systematic review of randomised controlled trials.
abstract: Metabolic syndrome (MS) is characterised by accumulation of CVD risk factors. The use of very long chain n-3 polyunsaturated fatty acids (VLC n3 PUFA) could potentially benefit MS by reducing risk factors. To better understand the possible VLC n3 PUFA benefits, the literature was systematically reviewed for randomised controlled trials (RCT) that published effects of VLC n3 PUFA on MS patients. 17 RCT fulfilled the inclusion criteria and were analysed for relevance to the research question. The available RCT convincingly show that the administration of VLC n3 PUFA doses > 1 g for at least 3 months produces a significant reduction of triglycerides ranging from 7 % to 25 %. These results confirm the hypotriglyceridemic effect of VLC n3 PUFA in MS patients. The triglyceride lowering may produce further benefits by reducing the % of pro-atherogenic small dense LDL particles (sdLDL) and also perhaps by ameliorating the inflammatory process associated with MS. High doses of VLC n3 PUFA ( ≥ 3 g/day) may produce further TAG reductions but could raise other risk factors such as LDL-C. No clear effects were found on other MS markers. The combination of VLC n3 PUFA plus a statin may be useful to prevent the occurrence of coronary events. More studies are needed using different amounts of VLC n3 PUFA, time lengths, dietary backgrounds and different profiles of MS patients before clear recommendations can be made.
authors.affiliation: Estación Experimental Zaidín, Consejo Superior de Investigaciones Científicas, Spanish Ministry of Economic Affairs and Competitiveness. Profesor Albareda 1, Granada 18008, Spain. eduardo.lopezhuertas@eez.csic.es
authors.forename: Eduardo
authors.initials: E
authors.lastname: Lopez-Huertas
mesh_terms: D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D004281:Docosahexaenoic Acids / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D015118:Eicosapentaenoic Acid / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000097:blood / Q000517:prevention & control; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy*; D014280:Triglycerides / Q000097:blood*
chemical_list: D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D014280:Triglycerides; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid